PSR Orphan Experts, Raremark announce rare disease tieup

London cityscape
London cityscape

The Netherlands-based orphan drug consulting and research company PSR Orphan Experts has signed a pact with Raremark, a new online service for families affected by rare disease, on a partnership designed to speed up the development of new treatments.

This new collab will use the companies’ complementary experience and capabilities to address the unique challenges involved in clinical research in orphan indications--which typically struggles with patient recruitment, given the small patient population for rare diseases.

London’s Raremark said it will engage families in the clinical trial process, helping them understand what taking part in a study means, and keeping them informed while participating in one.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Meanwhile PSR will provide strategic and operational consulting, in addition to its traditional CRO services.

“Most of the 7,000 known rare diseases lack approved drugs, meaning that clinical trials may be the only opportunity for people affected to access treatments,” said Roger Legtenberg, CEO of PSR.

“The rare disease community is generally very active, but there is a need for increased awareness that clinical trials are an option. We believe Raremark’s approach of engaging rare disease patients and families will bring benefits for all involved in drug development.”

Julie Walters, Raremark’s founder, added: “We’re impressed by PSR’s genuine commitment to the patient community, its sole focus on orphan disease, and the high caliber of its management team and long-standing relationships with specialist research centers.”

-check out the release

Suggested Articles

IQVIA has kick-started a new matchmaking trial service to “accelerate treatment and vaccine development” against COVID-19.

The move sees Evotec establish a 20-person team in Austria and sign up to work on programs for its Japanese partner.

Back in 2016, Pfizer signed up with CRO Icon to help it, alongside other CROs PPD and Parexel, run its vast trial network.